- 著者
- Ryutaro SHIMAZAKI Kohji KUSANO
- 出版者
- Catalyst Unit
- 雑誌
- Translational and Regulatory Sciences (ISSN:24344974)
- 巻号頁・発行日
- vol.3, no.3, pp.122-124, 2021 (Released:2021-12-24)
- 参考文献数
- 12
Sendai virus (SeV) vectors are able to infect a diverse range of cells. They have a high affinity for epithelial cells in the respiratory tract, which provides advantageous properties for intranasal inoculation. Vaccination of the respiratory tract, the main route of infection for Coronavirus (COVID-19), can strongly induce mucosal immunity, which is difficult to induce through injected vaccines, in addition to systemic immunity in a manner similar to innate immunity. A SeV vector vaccine carrying part of the SARS-CoV-2 spike-protein gene showed high immunogenicity in pharmacological studies using intranasally inoculated rodents and is a promising next-generation vaccine.